Takeda Pharmaceutical (4502) Key takeaways from management meeting

Research evidence excerpt

Takeda Pharmaceutical (4502) Key takeaways from management meeting

J P M O R G A N Asia Pacific Equity Research

18 May 2026

Takeda Pharmaceutical (4502) Neutral

4502.T, 4502 JP

Key takeaways from management meeting Price (15 May 26):¥5,277

Price Target (Dec-26):¥4,900

Takeda Pharmaceutical held a management meeting on May 15 from 08:30 JST. Japan Equity Research

Main topics of discussion are outlined below. Takeda confirmed plans to accelerate

Biotechnology & Pharmaceuticals/

its organization by reducing layers, standardizing processes, and using AI under Medical Technologies & Services

the leadership of incoming CEO Julie Kim, and to deliver growth and improve AC Seiji Wakao, Ph.D.

shareholder value during Horizon Two starting with the launch of three new

(81-3) 6736-8612

products in the next 12 months. seiji.wakao@jpmorgan.com

• Incoming CEO Julie Kim: Changes: Takeda’s main therapeutic areas are Yugo(81-3) 6736-8635R. Kamimura, Ph.D.

unchanged. Specifically, it will concentrate on gastrointestinal/inflammatory yugo.kamimura@jpmorgan.com

bowel disease (IBD), neuroscience (orexin), and plasma-derived therapies

Naoko Saito

(PDT), and will not enter the weight loss field. Takeda’s corporate culture is (81-3) 6736-8693

also unchanged. Main changes comprise organizational reforms to reduce naoko.saito@jpmorgan.com

layers and the pursuit of standardization and streamlining based on the JPMorgan Securities Japan Co., Ltd.

transformation program. Ms. Kim said it is her responsibility to ensure the

steady launch of new products to deliver growth in Horizon Two. Takeda aims

to improve shareholder value by launching three new products over the next 12

months, by using technology to raise productivity, and by accelerating growth

based on the late-stage pipeline.